Table 1.
Description of the studies and participant baseline characteristics by case-control status
| Characteristics | HAW (Hawaii Ovarian Cancer Study) | NECC (New England Case Control Study of Ovarian Cancer) |
All | ||||
|---|---|---|---|---|---|---|---|
| Source | Hawaii, Population-based | New England, Population-based | USA, Population-based | ||||
| Cases | Controls | Cases | Controls | Cases | Controls | OR (95% CI)* | |
| Participation rate | 65% | 68% | 72% | 69% | |||
| No. (%) of participants | 302 (34) | 592 (66) | 723 (40) | 1095 (60) | 1025 (38) | 1687 (62) | |
| No. (%) of participants with NSAID data available |
217 (34) | 419 (66) | 723 (40) | 1095 (60) | 940 (38) | 1514 (62) | |
| Age (SD; range in years) | 56.2 (12.9; 22-87) | 55.2 (13.9; 19-88) | 53.9 (11.5; 20-76) | 51.0 (13.0; 16-77) | 54.6 (12.0; 20-87) | 52.5 (13.4; 16-88) | |
| Ethnicity | |||||||
| White non-Hispanic | 70 (23) | 154 (26) | 723 (100) | 1095 (100) | 793 (77) | 1249 (74) | |
| Asian | 144 (48) | 282 (48) | - | - | 144 (14) | 282 (17) | |
| Mixed/Other | 88 (29) | 156 (26) | - | - | 88 (9) | 156 (9) | |
| Education | |||||||
| High school or less | 123 (41) | 177 (30) | 246 (34) | 330 (30) | 369 (36) | 507 (30) | 1.00 (reference) |
| Some college | 94 (31) | 196 (33) | 184 (25) | 320 (29) | 278 (27) | 516 (31) | 0.84 (0.61-1.17) |
| College/graduate school | 85 (28) | 219 (37) | 293 (41) | 445 (41) | 378 (37) | 664 (39) | 0.96 (0.78-1.17) |
| Family history of breast and/or ovarian cancer |
|||||||
| Yes | 58 (19) | 74 (13) | 133 (18) | 150 (14) | 191 (19) | 224 (13) | 1.40 (1.12-1.75) |
| No | 244 (81) | 518 (87) | 590 (82) | 945 (86) | 834 (81) | 1463 (87) | 1.00 (reference) |
| Hormonal contraceptive use | |||||||
| Yes | 131 (43) | 402 (68) | 342 (47) | 686 (63) | 473 (46) | 1088 (64) | 0.54 (0.45-0.65) |
| No | 171 (57) | 190 (32) | 381 (53) | 409 (37) | 552 (54) | 599 (36) | 1.00 (reference) |
| Menopausal status | |||||||
| Premenopausal | 93 (31) | 224 (38) | 269 (37) | 510 (47) | 367 (36) | 736 (44) | 1.00 (reference) |
| Postmenopausal | 209 (69) | 368 (62) | 454 (63) | 585 (53) | 658 (64) | 951 (56) | 1.25 (0.94-1.66) |
| Menopausal hormone use | |||||||
| None | 119 (57) | 163 (44) | 311 (69) | 372 (63) | 430 (65) | 535 (56) | 1.00 (reference) |
| Estrogen only | 52 (25) | 88 (24) | 73 (16) | 92 (16) | 125 (19) | 180 (19) | 1.03 (0.77-1.36) |
| Estrogen and progestin | 38 (18) | 117 (32) | 70 (15) | 121 (21) | 108 (16) | 238 (25) | 0.74 (0.56-0.99) |
| Rs5275 C allele frequency | 0.31 | 0.32 | 0.33 | 0.34 | 0.33 | 0.34 | |
| NSAID use by type | |||||||
| Nonusers | 101 (47) | 148 (35) | 481 (67) | 679 (62) | 582 (62) | 827 (55) | 1.00 (reference) |
| Aspirin | 31 (14) | 87 (21) | 105 (14) | 140 (13) | 136 (14) | 227 (15) | 0.84 (0.66-1.08) |
| Nonaspirin NSAIDs | 46 (21) | 91 (22) | 94 (13) | 201 (18) | 140 (15) | 292 (19) | 0.79 (0.62-1.01) |
| Both | 39 (18) | 93 (22) | 43 (6) | 75 (7) | 82 (9) | 168 (11) | 0.72 (0.53-0.98) |
| Any NSAID | 116 (53) | 271 (65) | 242 (33) | 416 (38) | 358 (38) | 687 (45) | 0.79 (0.67-0.95) |
*
Odds ratios (OR) and 95% confidence intervals (CI) from a multivariate logistic regression model that included age, ethnicity, education, family history of breast and/or ovarian cancer, and use of contraceptive and menopausal hormones, when applicable. P for heterogeneity of genotype distribution among white control individuals by study=0.62
‡
P for the goodness of fit chi-square test testing for consistency of genotype with Hardy-Weinberg equilibrium.